Lupin launches contraceptive drug in US
New Delhi: Drug maker Lupin launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets, used to prevent pregnancy, in the US market.
The company has launched the product in the US after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing.
Approval was granted in the strengths of 3 mg/ 0.02mg/ 0.451 mg and 0.451 mg.
Lupin's product is a generic equivalent of Bayer's Beyazs tablets.
Quoting IQVIA MAT June 2018 data, Lupin said Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets had annual sales of approximately USD 80.8 million in the US.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd